Acumen Pharmaceuticals (ABOS) Cash from Operations (2020 - 2026)
Acumen Pharmaceuticals recorded quarterly Cash from Operations of 24128000.0 in Q1 2026, down 26.35% quarter-over-quarter from 19096000.0 in Q4 2025, and up 29.29% year-over-year from 18662363.15 in Q1 2025.
Acumen Pharmaceuticals' Cash from Operations history runs 7 years deep, the most recent figure standing at 24128000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 29.29% year-over-year to 24128000.0; the TTM figure through Mar 2026 stood at 105545000.0 (down 2.99% YoY), while the FY2025 annual figure was 115538000.0, down 34.01% from the prior year.
- Cash from Operations came in at 24128000.0 for Q1 2026 at Acumen Pharmaceuticals, down from 19096000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 6468000.0 in Q2 2022 to a low of 34121000.0 in Q1 2025.
- A 5-year average of 17888117.65 and a median of 16545000.0 in 2024 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations sank 250.17% in 2022 and increased 29.83% in 2025, its largest moves.
- Acumen Pharmaceuticals' Cash from Operations stood at 11203000.0 in 2022, then increased by 25.79% to 8314000.0 in 2023, then tumbled by 227.34% to 27215000.0 in 2024, then climbed by 29.83% to 19096000.0 in 2025, then decreased by 26.35% to 24128000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 24128000.0, 19096000.0, and 30489000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - | -24.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.13 Mn |
| Mar 31, 2026 | -24.13 Mn |
| Dec 31, 2025 | -19.10 Mn |
| Dec 31, 2025 | -19.10 Mn |
| Sep 30, 2025 | -30.49 Mn |
| Sep 30, 2025 | -30.49 Mn |
| Jun 30, 2025 | -31.83 Mn |
| Jun 30, 2025 | -31.83 Mn |
| Mar 31, 2025 | -34.12 Mn |
| Mar 31, 2025 | -34.12 Mn |
| Dec 31, 2024 | -27.22 Mn |
| Dec 31, 2024 | -27.22 Mn |
| Sep 30, 2024 | -24.60 Mn |
| Sep 30, 2024 | -24.60 Mn |
| Jun 30, 2024 | -16.55 Mn |
| Jun 30, 2024 | -16.55 Mn |
| Mar 31, 2024 | -17.86 Mn |
| Mar 31, 2024 | -17.86 Mn |
| Dec 31, 2023 | -8.31 Mn |
| Dec 31, 2023 | -8.31 Mn |
| Sep 30, 2023 | -12.91 Mn |
| Sep 30, 2023 | -12.91 Mn |
| Jun 30, 2023 | -11.67 Mn |
| Jun 30, 2023 | -11.67 Mn |
| Mar 31, 2023 | -10.18 Mn |
| Mar 31, 2023 | -10.18 Mn |
| Dec 31, 2022 | -11.20 Mn |
| Dec 31, 2022 | -11.20 Mn |
| Sep 30, 2022 | -9.18 Mn |
| Sep 30, 2022 | -9.18 Mn |
| Jun 30, 2022 | -6.47 Mn |
| Jun 30, 2022 | -6.47 Mn |
| Mar 31, 2022 | -8.30 Mn |
| Mar 31, 2022 | -8.30 Mn |
| Dec 31, 2021 | -3.64 Mn |
| Dec 31, 2021 | -3.64 Mn |
| Sep 30, 2021 | -7.69 Mn |
| Sep 30, 2021 | -7.69 Mn |
| Jun 30, 2021 | -4.26 Mn |
| Jun 30, 2021 | -4.26 Mn |
| Mar 31, 2021 | -2.37 Mn |
| Mar 31, 2021 | -2.37 Mn |
| Dec 31, 2020 | -2.86 Mn |
| Dec 31, 2020 | -2.86 Mn |
| Sep 30, 2020 | -1.28 Mn |
| Sep 30, 2020 | -1.28 Mn |